Risk reduction strategies are most relevant to women identified as carrying a BRCA1 or BRCA2 mutation who have not yet developed cancer and the role of risk-reducing surgery in the management of hereditary breast and ovarian cancer is already well established (Hartmann and Lindor 2015). The gene discussed is BRCA2; the disease is ovarian cancer.